Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt

A phase III clinical trial showed gemcitabine chemotherapy combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib significantly improved overall survival in patients with advanced pancreatic cancer. Therefore, we studied whether addition of gemcitabine to erlotinib...

Full description

Bibliographic Details
Main Authors: Bartholomeusz, Chandra, Yamasaki, Fumiyuki, Saso, Hitomi, Kurisu, Kaoru, Hortobagyi, Gabriel N., Ueno, Naoto T.
Format: Online
Language:English
Published: Ivyspring International Publisher 2011
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3157020/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3157020/

Similar Items